Investor Relations

Latest Financial Results

Company Overview

bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, with the potential to dramatically increase overall diagnostic accuracy of lung cancer leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

Stock Snapshot

IR Contacts


bioAffinity Technologies, Inc.
22211 West Interstate 10
Suite 1204
San Antonio, TX 78257
T: 210-698-5334

Investor Relations

Tiberend Strategic Advisors, Inc.
35 W. 35th Street
11th Floor
New York, NY 10001-0080
T: 212-375-2689

Jonathan Nugent

David Irish

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, New York 11598
T: 212-828-8436 (Ext. 118)
F: 646-536-3179